Junshi Biosciences Announces Toripalimab's NDA Accepted by

SHANGHAI, China, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...

Related Keywords

Shanghai ,China ,Canada ,Beijing ,Singapore ,San Francisco ,California ,United States ,Maryland ,Guangzhou ,Guangdong ,Australia ,United Kingdom ,Suzhou ,Jiangsu ,American ,Chinese ,Zhi Li ,Junshi Biosciences ,Drug Administration ,Oncology Center ,Regulatory Agency ,Journal Of The American Medical Association ,European Union ,World Health Organization ,Pr Team ,Shanghai Junshi Biosciences Co Ltd ,Australia Therapeutic Goods Administration ,American Society Of Clinical Oncology ,Health Canada ,Ir Team ,Singapore Health Sciences Authority ,National Reimbursement Drug List ,European Medicines Agency ,New Drug Application ,Project Orbis ,Clinical Oncology ,Nature Medicine ,American Medical Association ,Southeast Asia ,Biologics License Application ,Orphan Drug ,For Global ,Hong Kong Stock Exchange 1877 Hk ,